Oruka Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 2, 2025, details the results of Oruka Therapeutics, Inc.'s Annual Meeting of Stockholders held on that date. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol ORKA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance.
Material Changes and Voting Results
Stockholders voted on four proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected Carl Dambkowski and Peter Harwin as Class I directors. Carl Dambkowski received 26,047,914 votes for and 2,291 withheld. Peter Harwin received 25,935,823 votes for and 114,382 withheld. There were 732,854 broker non-votes.
- Proposal 2 (Ratification of Auditor): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2025. Votes cast were 26,781,030 for, 1,848 against, and 181 abstaining.
- Proposal 3 (Executive Compensation): Stockholders approved the non-binding advisory vote on executive compensation. Votes cast were 25,824,834 for, 88,740 against, and 136,631 abstaining.
- Proposal 4 (Frequency of Compensation Votes): Stockholders approved a one-year frequency for future advisory votes on executive compensation. Votes for 1-year frequency were 25,854,625, compared to 807 for 2-year and 54,626 for 3-year frequency.
Guidance, Outlook, and Management Commentary
Following the meeting, the Board of Directors determined that future advisory votes on executive compensation will be held annually, aligning with the stockholder preference expressed in Proposal 4. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the standard governance disclosures.
Key Facts for Investor Verification
- Verify the definitive proxy statement filed on April 18, 2025, for detailed biographies of the elected directors and full executive compensation disclosures.
- Confirm the appointment of PricewaterhouseCoopers LLP as the independent auditor for the 2025 fiscal year.
- Note the Board's commitment to annual executive compensation advisory votes based on the June 2, 2025, stockholder vote.
- Review the significant number of broker non-votes (732,854) recorded for the director election and compensation proposals.